Pharmagreen Biotech Stock Shares Owned By Institutions
| PHBI Stock | USD 0 0.0001 5.56% |
Pharmagreen Biotech fundamentals help investors to digest information that contributes to Pharmagreen Biotech's financial success or failures. It also enables traders to predict the movement of Pharmagreen Pink Sheet. The fundamental analysis module provides a way to measure Pharmagreen Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharmagreen Biotech pink sheet.
Pharmagreen |
Pharmagreen Biotech Company Shares Owned By Institutions Analysis
Pharmagreen Biotech's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 0.0% of Pharmagreen Biotech are shares owned by institutions. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The shares owned by institutions for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Options Analysis Now
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios |
| All Next | Launch Module |
Pharmagreen Fundamentals
| Return On Asset | -2.3 | |||
| Current Valuation | 3.12 M | |||
| Shares Outstanding | 454.76 M | |||
| Shares Owned By Insiders | 18.63 % | |||
| EBITDA | (828.26 K) | |||
| Net Income | (875.48 K) | |||
| Cash And Equivalents | 24.26 K | |||
| Total Debt | 119.47 K | |||
| Current Ratio | 0.10 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (426.57 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 1.44 | |||
| Market Capitalization | 2.96 M | |||
| Total Asset | 208.97 K | |||
| Z Score | 4.5 | |||
| Net Asset | 208.97 K |
About Pharmagreen Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmagreen Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmagreen Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmagreen Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Pharmagreen Pink Sheet
Pharmagreen Biotech financial ratios help investors to determine whether Pharmagreen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmagreen with respect to the benefits of owning Pharmagreen Biotech security.